Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas

British Journal of Cancer

Volumn 76, Issue 3, 1997, Pages 340-346

  Charpin, C ^a,c   Garcia, S ^b   Bouvier, C ^b   Devictor, B ^a   Andrac, L ^a   Lavaut, M N ^a   Allasia, C ^a  

^a Laboratoire de Biopathologie de l'Adhésion et de la Signalisation   (France)

^b HÔPITAL NORD   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Automated and quantitative immunohistochemistry; Bcl 2 protein; Breast carcinoma

Indexed keywords

ESTROGEN RECEPTOR; GLYCOPROTEIN P; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; AUTOANALYSIS; BREAST CARCINOMA; CANCER GRADING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; STATISTICAL ANALYSIS;

EID: 0030751543     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.388     Document Type: Article

References (43)

1. Alnemri ES, Fernandas TF, Haldar S, Croce CM and Litwack G (1992) Involvement of bcl-2 in glucocorticoid-induced apoptosis of human pre-B leukemias. Cancer Res 52: 491-495
2. Baba M, Hideshima T, Shinohara T, Yamashita JI and Shirakusa T (1996) Immunohistochemical analysis of bcl-2 and p53 protein in breast carcinoma. Int J Oncol 8: 355-358
3. Bloom HJG and Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377
4. Brugal G, Garbay C, Giroud F and Adhel D (1979) A double scanning microphotometer for image analysis: hardware, sofware and biomedical application. J Histochem Cytochem 27: 144
5. Charpin C and Pellissier JF (1994) Marqueurs moléculaires dans les cancers du sein: aspect pratique et évaluation morphologique. Bull Acad Natl Med 178: 475-493
6. Charpin C, Andrac L, Vacheret H, Habib MC, De Victor B, Lavaut MN and Toga M (1988a) Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma: a correlation of immunodetection in tissue sections and morphological data and estrogen and progesterone receptor immunocytochemical assays. Cancer Res 48: 4368-4374
7. Charpin C, Jacquemier J, Andrac L, Vacheret H, Habib MC, DeVictor B and Toga M (1988b) Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in non malignant and malignant breast isorders. Am J Pathol 132: 199-211
8. Charpin C, Martin P, Devictor B, Lavaut MN, Habib MC and Toga M (1988c) Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran coated charcoal assays and morphological data. Cancer Res 48: 1578-1586
9. Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut MN, Allasia C and Piana L (1993) Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Path 170: 463-470
10. Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut MN, Allasia C, Horschowski N and Piana L (1994) Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst 86: 1539-1545
11. Charpin C, Devictor B, Andrac L, Amabile J, Bergeret D, Lavaut MN, Allasia C and Piana L (1995a) P-53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol 26: 159-166
12. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN and Piana L (1995b) CD 31 quantitative immunohistochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Path 103: 443-448
13. Chen-Levy S and Cleary ML (1990) Membrane topology of the bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 265: 4929-1433
14. Clearly ML, Smith SD and Sklar J (1986) Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t (14;18) translocation. Cell 47: 19-28
15. Chen-Levy Z, Nourse J and Cleary MZ (1989) The bcl-2 candidate proto-oncogene product is a 24-kD integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t [14;18] translocation. Mol Cell Biol 9: 701-710
16. Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280
17. Fisher TC, Milner AE, Gregory CD, Jackman AZ, Wynne-Aherne G and Hartley JA (1993) bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321-3327
18. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M and Beach D (1995) CDC25 Phosphatases as potential human oncogenes. Science 269: 1575-1577
19. Galea MH, Blarney RW, Elston CE and Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Br Cancer Res Treat 22: 207-219
20. Gee JMW, Robertson JFR, Ellis IO, Willsher P McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blarney RW and Nicholson RI (1994) Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628
21. Grogan TM, Casey TT, Miller PC, Rangel CS, Nunnery DW and Naglo RB (1993) Automation of immunohistochemistry. Adv Path Lab Med 6: 253-283
22. Grogan TM, Rangel C, Rimsza L, Bellamy W, Martel R, McDaniel D, McGraw B, Richards W, Richter L, Rodgers P, Rybski J, Showalter W, Vela E and Zeheb R (1995) Kinetic-Mode, automated double-labeled immunohistochemistry and in situ hybridation in diagnostic pathology. Adv Path Lab Med 8: 79-99
23. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097
24. Hellemans P, Van Dam PA, Weyler J, Van Oosterom AT, Buytaert P and Van Marck E (1995) Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360
25. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmever SJ (1990) bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336
26. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE and Dowsett M (1994) Modulation of bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 11: 1662-1669
27. Korsmever SJ (1992) bcl-2 initiates a new category of oncogene regulators of cell death. Blood 80: 879-886
28. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC (1993) Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701-4714
29. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos E and Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariated analysis of 1262 invasive ductal breast carcinomas Cancer 64: 1914-1921
30. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL (1994) bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139
31. Lotem J and Sachs L (1993) Regulation by bcl-2, myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and detective myeloid leukemic cells. Cell Growth Different 4: 41-47
32. Maudelonde T, Brouillet JP, Roger P, Gissaudier V, Pages A and Rochefort H (1993) Immunostaining of cathepsin D in breast cancer: quantification by computerized image analysis and correlation with cytosolic assay. J Path 170: 463-470
33. Miyashita T and Reed JC (1992) bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glycocorticoids and multiple chemotherapeutic drugs. Cancer Res 52: 5407-5411
34. Miyashita T and Reed JC (1993) bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157
35. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, Reed R, Seen HJ, Goldhirsh A and Dyer MJS (1994) Expression of bcl-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 5: 409-414
36. Sachs L and Lotem J (1993) Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82: 15-21
37. Siegel RM, Katsumata M, Miyashita T, Louie DC, Greene MI and Reed JC (1992) Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci 89: 7003-7007
38. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fonzo G, Rilke F and Veronesi U (1944) The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 7: 499-504
39. Tsujimoto Y, Cossman J, Jaffe E and Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphonia. Science 228: 1440-1443
40. Tsujimoto Y and Croce CM (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218
41. Vaux D, Cory S and Adams J (1988) bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442
42. Wang Y, Szekely L, Okan I, Klein G and Wiman KG (1993) Wild-type p53 triggered apoptosis is inhibited by bcl-2 in a C-myc-induced T-cell lymphoma line. Oncogene 82: 1994-2004
43. Wyllie AH, Morris RG, Smith AL and Dunlop D (1987) Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 153: 313-319